Advanced Therapy Medicinal Products CDMO Market Overview
As per Econ Market Research analysis, the Global Advanced Therapy Medicinal Products CDMO Market valuation stood at US$ 11.12 Billion in 2026 and is expected to reach US$ 53.11 Billion by 2035, growing at a steady CAGR of 18.97% from 2026 to 2035. 2025 serves as the base year.
The Global Advanced Therapy Medicinal Products (ATMP) Contract Development and Manufacturing Organization (CDMO) market has witnessed significant growth in recent years, reflecting the expanding landscape of advanced therapies in the pharmaceutical and Biotechnology sectors. Advanced Therapy Medicinal Products encompass cell and gene therapies, offering innovative solutions for previously incurable diseases. These therapies involve the manipulation of living cells or genetic material to treat or prevent diseases at the genetic level, showcasing a paradigm shift in healthcare. The ATMP CDMO market plays a pivotal role in supporting the development and manufacturing of these ground-breaking therapies by providing specialized services such as process development, manufacturing, and analytical testing.
The market for ATMP CDMOs is expanding as a result of pharmaceutical companies outsourcing their manufacturing processes to specialised CDMOs in response to the growing demand for advanced therapies. These companies provide the infrastructure, know-how, and regulatory compliance required for the intricate and strictly regulated manufacturing of cutting-edge treatments. A wide variety of CDMOs serving various stages of the ATMP development lifecycle, from early-stage process development to large-scale commercial manufacturing, define the market.
Advanced Therapy Medicinal Products CDMO Dynamics
The need for novel therapeutic strategies has increased due to the rising incidence of complicated and previously incurable diseases, especially those involving cell and gene therapies. Due to the increased demand, biotechnology and pharmaceutical companies are collaborating with specialised ATMP CDMOs to take advantage of their experience navigating the complex manufacturing processes involved in producing these cutting-edge therapies.
The industry dynamics are further influenced by the expanding landscape of clinical trials for ATMPs, as regulatory agencies continue to provide frameworks for the development and commercialization of these ground-breaking treatments. The need for scalable and cost-effective manufacturing solutions has led to a rise in strategic collaborations and partnerships between pharmaceutical companies and CDMOs, fostering a dynamic and collaborative ecosystem. These partnerships aim to optimize the efficiency of ATMP development by leveraging the complementary strengths of each party involved.
Advanced Therapy Medicinal Products CDMO Drivers
Increasing Prevalence of Complex Diseases and Unmet Medical Needs
The global ATMP CDMO market is significantly driven by the rising incidence of complex diseases, such as cancers and different genetic disorders, as well as an increase in the number of unmet medical needs. Novel treatment modalities, such as cell and gene therapies, are available for conditions for which there are few or no effective therapeutic options. Pharmaceutical companies are enlisting ATMP CDMOs to leverage their specialised manufacturing capabilities in response to the growing demand for innovative therapies that address unmet needs, which is driving market growth.
Advancements in Technology and Manufacturing Processes
Continuous advancements in technology and manufacturing processes within the ATMP space contribute as a driving force for the CDMO market. Technological innovations enhance the efficiency, scalability, and cost-effectiveness of manufacturing advanced therapies. This includes improvements in vector design, gene editing technologies, and process automation, enabling CDMOs to meet the increasing demand for large-scale production. The integration of cutting-edge technologies attracts pharmaceutical companies seeking state-of-the-art facilities and expertise for the development and production of advanced therapies, positioning the ATMP CDMO market at the forefront of innovation.
Restraints:
Complex Regulatory Landscape and Stringent Quality Standards
The ATMP CDMO market faces challenges associated with the complex regulatory landscape governing the development and manufacturing of advanced therapies. Stringent quality standards and regulatory requirements pose significant barriers, requiring substantial investments in compliance and validation processes. This complexity can result in extended timelines and increased costs, impacting the overall efficiency of ATMP development and hindering market growth.
High Initial Capital Requirements and Manufacturing Challenges
The market participants are limited by the significant initial capital needs for the establishment and upkeep of cutting-edge manufacturing facilities for ATMPs. Significant upfront costs are associated with the specialised infrastructure and equipment required for the production of gene and cell therapies. Furthermore, there are difficulties that could restrict the scalability of operations and impede market expansion due to the intrinsic complexity of the manufacturing processes for these therapies, such as maintaining cell viability during production and guaranteeing consistent product quality.
Opportunities:
Expansion of Clinical Trials and Therapeutic Applications
The increasing number of clinical trials for cell and gene therapies presents a substantial opportunity for the ATMP CDMO market. As more therapies progress through the development pipeline, CDMOs stand to benefit from the expanding demand for manufacturing services. Moreover, the exploration of new therapeutic applications beyond oncology, such as in rare diseases and autoimmune disorders, opens avenues for CDMOs to diversify their service offerings and capture emerging market opportunities.
Segment Overview
By Product
The ATMP market encompasses several product types, including gene therapy, cell therapy, tissue-engineered products, and other emerging modalities. Gene therapy involves the introduction, deletion, or replacement of genetic material to treat or prevent diseases at the genetic level. Cell therapy focuses on using living cells, often modified or engineered, for therapeutic purposes. Tissue-engineered products involve the creation of biological substitutes to repair or replace damaged tissues.
By Phase
The developmental phases of advanced therapies are categorized into Phase I, Phase II, Phase III, and Phase IV. Phase I involves initial human testing to assess safety and dosage, Phase II explores efficacy in a larger sample, Phase III evaluates safety and efficacy in a broader patient population, and Phase IV involves post-marketing surveillance. Understanding the developmental phase of each therapy is crucial for assessing its progression toward commercialization and widespread clinical use.
By Indication
The therapeutic indications for advanced therapies span a wide range of medical fields. These include oncology, addressing various forms of cancer, cardiology, focusing on heart-related conditions, central nervous system applications for neurological disorders, musculoskeletal treatments for bone and muscle-related issues, infectious disease interventions, dermatology for skin-related conditions, endocrine, metabolic, and genetic therapies, immunology &, inflammation targeting immune-related disorders, ophthalmology for eye-related conditions, and other indications that may emerge as the field evolves. Each indication reflects the diverse applications of advanced therapies in addressing a spectrum of diseases and medical challenges.
Advanced Therapy Medicinal Products CDMO Overview by Region
North America stands as a major hub for ATMP development and manufacturing, driven by a robust biotechnology sector, significant research and development activities, and supportive regulatory frameworks. The region',s leadership is underscored by a high concentration of pharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs) specializing in advanced therapies, particularly in the United States.
Europe is not far behind, with the EU creating an environment that is conducive to ATMP innovation through joint research projects and regulatory actions. An important regulatory pathway for ATMP approvals is provided by the European Medicines Agency (EMA). As major players in the ATMP market, nations like the UK, Germany, and Switzerland are home to several manufacturing facilities and clinical trials.
Due to its rapidly developing healthcare infrastructure, expanding patient base, and rising investments in life sciences, Asia-Pacific offers significant growth potential. Research and development on ATMPs has advanced significantly in nations like China, Japan, and South Korea. Additionally, favourable regulatory reforms in Japan have facilitated expedited approval processes for Regenerative Medicine products, further propelling the market.
Advanced Therapy Medicinal Products CDMO Market Competitive Landscape
Key industry players are strategically positioning themselves to capitalize on the burgeoning demand for advanced therapies, such as gene and cell therapies, that are revolutionizing the treatment landscape. Prominent pharmaceutical companies, including Novartis, Gilead Sciences, and Spark Therapeutics, have established themselves as frontrunners in the ATMP market, leveraging their expertise in research, development, and commercialization. These companies often engage in strategic collaborations and partnerships with CDMOs to enhance their manufacturing capabilities and expand their portfolios.
CDMOs play a crucial role in the competitive landscape, offering specialized services in process development, manufacturing, and analytical testing for advanced therapies. Leaders in this space, such as Lonza Group, Catalent, and Thermo Fisher Scientific, provide end-to-end solutions to pharmaceutical companies, addressing the complex manufacturing requirements of ATMPs. The competitive dynamics involve CDMOs continuously investing in infrastructure, technological capabilities, and regulatory compliance to meet the evolving needs of the industry.
Advanced Therapy Medicinal Products CDMO Market Key Players:
AGC Biologics?
WuXi Advanced Therapies?
Celonic Group?
Catalent Inc.?
Lonza
Thermo Fisher Scientific
Charles River Laboratories
Patheon
Rentschler Biopharma SE
CGT Catapult
Advanced Therapy Medicinal Products CDMO Recent Developments
Feb 2022, Recipharm, a worldwide contract development and manufacturing organization (CDMO), is enhancing its capabilities in emerging biologic modalities by acquiring Vibalogics. Vibalogics, a virotherapy CDMO and part of Ampersand Capital Partners', portfolio, is a prominent player in producing oncolytic viruses, viral Vaccines, and gene therapies. The company provides a comprehensive range of services, including process and analytical development, manufacturing, testing, and fill-finish services in these areas.
Jan 2022, FUJIFILM Corporation, led by President and CEO Teiichi Goto, has recently finalized an agreement to purchase a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. for a total of USD 100 million. Situated in Thousand Oaks, California, this facility possesses expandable capabilities and versatile infrastructure, enabling the production of both clinical and commercial cell therapies. This includes allogeneic T-cell and CAR T immunotherapies.\\.
Advanced Therapy Medicinal Products CDMO Report Segmentation
Advanced Therapy Medicinal Products CDMO Market Segmentation
| Segment Category | Segment Values |
|---|---|
| Product |
|
| Phase |
|
| Indication |
|
Key Players
- Lonza
- Catalent
- WuXi Advanced Therapies
- Thermo Fisher (Brammer Bio)
- Charles River
- Fujifilm Diosynth
- Hitachi Chemical
Table of Contents
1. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET–REPORT OVERVIEW
- 1.1. SCOPE OF THE REPORT
- 1.2. MARKET SEGMENT ANALYSIS
- 1.3. REGULATORY SCENARIO BY REGION/COUNTRY
- 1.4. MARKET INVESTMENT SCENARIO STRATEGIC
- 1.5. MARKET ANALYSIS BY BY PRODUCT (USD MILLION)
- 1.5.1 GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY BY PRODUCT (2026-2035)
- 1.5.2 GENE THERAPY
- 1.5.3 CELL THERAPY
- 1.5.4 TISSUE ENGINEERED PRODUCTS
- 1.5.5 OTHERS
- 1.6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY BY PRODUCT IN 2026 & 2035
- 1.7. MARKET ANALYSIS BY BY PHASE (USD MILLION)
- 1.7.1 GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY BY PHASE (2026-2035)
- 1.7.2 PRE-CLINICAL
- 1.7.3 PHASE I
- 1.7.4 PHASE II
- 1.7.5 PHASE III
- 1.7.6 COMMERCIAL
- 1.8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY BY PHASE IN 2026 & 2035
- 1.9. MARKET ANALYSIS BY BY INDICATION (USD MILLION)
- 1.9.1 GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY BY INDICATION (2026-2035)
- 1.9.2 ONCOLOGY
- 1.9.3 CARDIOLOGY
- 1.9.4 NEUROLOGY
- 1.9.5 OTHERS
- 1.10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY BY INDICATION IN 2026 & 2035
2. DRIVER RESTRAINT CHALLENGE AND OPPORTUNITIES OF ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET
- 2.1. DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
- 2.1.1 MARKET DRIVER ANALYSIS
- 2.1.2 MARKET RESTRAINT ANALYSIS
- 2.1.3 MARKET OPPORTUNITY
- 2.2. MARKET CHALLENGES
3. GLOBAL GROWTH TRENDS
- 3.1. INDUSTRY TRENDS
- 3.1.1 SWOT ANALYSIS
- 3.1.1.1 Strengths
- 3.1.1.2 Weaknesses
- 3.1.1.3 Opportunities
- 3.1.1.4 Threats
- 3.1.2 PESTEL ANALYSIS
- 3.1.2.1 Political Landscape
- 3.1.2.2 Economic Landscape
- 3.1.2.3 Social Landscape
- 3.1.2.4 Technological Landscape
- 3.1.2.5 Environmental Landscape
- 3.1.2.6 Legal Landscape
- 3.1.3 PORTER'S FIVE FORCES ANALYSIS
- 3.1.3.1 Bargaining Power of Suppliers
- 3.1.3.2 Bargaining Power of Buyers
- 3.1.3.3 Threat of Substitute
- 3.1.3.4 Threat of New Entrant
- 3.1.3.5 Competitive Rivalry
- 3.1.1 SWOT ANALYSIS
- 3.2. POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4. POST COVID ANALYSIS
- 4.1. COVID V ANALYSIS
- 4.2. COVID U ANALYSIS
- 4.3. COVID L ANALYSIS
- 4.4. COVID W ANALYSIS
5. COMPANIES ANALYSIS
- 5.1. PLAYERS COVERED: RANKING BY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET REVENUE
- 5.2. TOP COMPANIES MARKET SHARE (%)
6. EXECUTIVE SUMMARY
7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET FORECAST, 2022-2035, (USD MILLION)
- 7.1. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET REVENUE AND MARKET SHARE BY REGIONS
- 7.2. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY REGION (2022-2029)
- 7.3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY REGION (2030-2035)
- 7.3.1.1 North America
- 7.3.1.2 Europe
- 7.3.1.3 Asia Pacific
- 7.3.1.4 Latin America
- 7.3.1.5 Middle East & Africa
8. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 8.1. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 8.2. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 8.3. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 8.3.1.1 United States
- 8.3.1.2 Canada
- 8.3.1.3 Mexico
9. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 9.1. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 9.2. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 9.3. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 9.3.1.1 United Kingdom
- 9.3.1.2 Germany
- 9.3.1.3 France
- 9.3.1.4 Spain
- 9.3.1.5 Italy
- 9.3.1.6 Rest of Europe
10. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 10.1. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 10.2. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 10.3. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 10.3.1.1 China
- 10.3.1.2 India
- 10.3.1.3 Japan
- 10.3.1.4 Australia
- 10.3.1.5 South Korea
- 10.3.1.6 Rest of Asia Pacific
11. MIDDLE EAST AND AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 11.1. MIDDLE EAST AND AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 11.2. MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 11.3. MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 11.3.1.1 Saudi Arabia
- 11.3.1.2 South Africa
- 11.3.1.3 Rest of MEA
12. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 12.1. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 12.2. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 12.3. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 12.3.1.1 Brazil
- 12.3.1.2 Argentina
- 12.3.1.3 Rest of Latin America
13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SEGMENT BY BY PRODUCT, (USD MILLION)
- 13.1. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.2. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
- 13.3. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.4. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
- 13.5. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.6. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
- 13.7. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.8. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
- 13.9. MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.10. MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
- 13.11. SOUTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.12. SOUTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SEGMENT BY BY PHASE, (USD MILLION)
- 13.13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PHASE (2022-2029)
- 13.14. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PHASE (2030-2035)
- 13.15. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PHASE (2022-2029)
- 13.16. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PHASE (2030-2035)
- 13.17. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PHASE (2022-2029)
- 13.18. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PHASE (2030-2035)
- 13.19. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PHASE (2022-2029)
- 13.20. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PHASE (2030-2035)
- 13.21. MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PHASE (2022-2029)
- 13.22. MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PHASE (2030-2035)
- 13.23. SOUTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PHASE (2022-2029)
- 13.24. SOUTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY PHASE (2030-2035)
13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SEGMENT BY BY INDICATION, (USD MILLION)
- 13.25. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.26. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
- 13.27. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.28. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
- 13.29. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.30. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
- 13.31. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.32. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
- 13.33. MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.34. MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
- 13.35. SOUTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY INDICATION (2022-2029)
- 13.36. SOUTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET AND MARKET SHARE BY BY INDICATION (2030-2035)
14. COMPANY PROFILES
- 14.1. LONZA
- 14.1.1 COMPANY DETAIL
- 14.1.2 FINANCIALS (USD MILLIONS)
- 14.1.3 PRODUCT SUMMARY
- 14.1.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.2. CATALENT
- 14.2.1 COMPANY DETAIL
- 14.2.2 FINANCIALS (USD MILLIONS)
- 14.2.3 PRODUCT SUMMARY
- 14.2.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.3. WUXI ADVANCED THERAPIES
- 14.3.1 COMPANY DETAIL
- 14.3.2 FINANCIALS (USD MILLIONS)
- 14.3.3 PRODUCT SUMMARY
- 14.3.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.4. THERMO FISHER (BRAMMER BIO)
- 14.4.1 COMPANY DETAIL
- 14.4.2 FINANCIALS (USD MILLIONS)
- 14.4.3 PRODUCT SUMMARY
- 14.4.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.5. CHARLES RIVER
- 14.5.1 COMPANY DETAIL
- 14.5.2 FINANCIALS (USD MILLIONS)
- 14.5.3 PRODUCT SUMMARY
- 14.5.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.6. FUJIFILM DIOSYNTH
- 14.6.1 COMPANY DETAIL
- 14.6.2 FINANCIALS (USD MILLIONS)
- 14.6.3 PRODUCT SUMMARY
- 14.6.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.7. HITACHI CHEMICAL
- 14.7.1 COMPANY DETAIL
- 14.7.2 FINANCIALS (USD MILLIONS)
- 14.7.3 PRODUCT SUMMARY
- 14.7.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
15. CONCLUSION
16. REFERENCE LINK
17. APPENDIX
- 17.1. METHODOLOGY
- 17.2. RESEARCH DATA SOURCE
- 17.2.1 SECONDARY DATA
- 17.2.2 KEY DATA FROM SECONDARY
- 17.2.3 PRIMARY DATA
- 17.2.4 KEY DATA FROM PRIMARY
- 17.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
- 17.2.6 MARKET ESTIMATION
- 17.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
- 17.2.8 LEGAL DISCLAIMER
18. RESEARCH SCOPE
LIST OF TABLES
- TABLE 1. MARKET SEGMENT
- TABLE 2. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET GROWTH RATE BY BY PRODUCT (2026-2035)
- TABLE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET GROWTH RATE BY BY PHASE (2026-2035)
- TABLE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET GROWTH RATE BY BY INDICATION (2026-2035)
- TABLE 5. COMPANY'S RANK BY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET REVENUE
- TABLE 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET — MARKET SNAPSHOT & KEY BUYING CRITERIA, 2026–2035
- TABLE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY REGION, USD MILLION (2022-2029)
- TABLE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY REGION, (2022-2029)
- TABLE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY REGION, USD MILLION (2030-2035)
- TABLE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY REGION, (2030-2035)
- TABLE 13. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 14. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 15. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 16. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 17. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 18. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 19. MIDDLE EAST AND AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 20. MIDDLE EAST AND AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 21. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 22. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 23. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY COUNTRY, (2022-2029)
- TABLE 24. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 25. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY COUNTRY, (2030-2035)
- TABLE 26. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 27. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 28. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 29. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 30. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 31. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 32. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 33. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY COUNTRY, (2022-2029)
- TABLE 34. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 35. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY COUNTRY, (2030-2035)
- TABLE 36. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 37. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 38. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 39. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 40. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 41. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 42. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 43. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 44. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 45. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 46. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 47. REST OF EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 48. REST OF EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 49. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY COUNTRY, (2022-2029)
- TABLE 50. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 51. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY COUNTRY, (2030-2035)
- TABLE 52. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 53. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 54. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 55. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 56. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 57. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 58. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 59. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 60. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 61. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 62. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 63. REST OF ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 64. REST OF ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 65. MIDDLE EAST AND AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY COUNTRY, (2022-2029)
- TABLE 66. MIDDLE EAST AND AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 67. MIDDLE EAST AND AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY COUNTRY, (2030-2035)
- TABLE 68. MIDDLE EAST AND AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 69. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 70. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 71. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 72. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 73. REST OF MEA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 74. REST OF MEA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 75. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY COUNTRY, (2022-2029)
- TABLE 76. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 77. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY COUNTRY, (2030-2035)
- TABLE 78. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 79. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 80. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 81. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 82. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 83. REST OF LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2022-2029)
- TABLE 84. REST OF LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (USD MILLION) (2030-2035)
- TABLE 85. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 86. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 87. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 88. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 89. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 90. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 91. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 92. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 93. MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 94. MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 95. SOUTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 96. SOUTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 97. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PHASE, USD MILLION (2022-2029)
- TABLE 98. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PHASE, USD MILLION (2030-2035)
- TABLE 99. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PHASE, USD MILLION (2022-2029)
- TABLE 100. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PHASE, USD MILLION (2030-2035)
- TABLE 101. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PHASE, USD MILLION (2022-2029)
- TABLE 102. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PHASE, USD MILLION (2030-2035)
- TABLE 103. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PHASE, USD MILLION (2022-2029)
- TABLE 104. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PHASE, USD MILLION (2030-2035)
- TABLE 105. MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PHASE, USD MILLION (2022-2029)
- TABLE 106. MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PHASE, USD MILLION (2030-2035)
- TABLE 107. SOUTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PHASE, USD MILLION (2022-2029)
- TABLE 108. SOUTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY PHASE, USD MILLION (2030-2035)
- TABLE 109. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 110. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 111. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 112. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 113. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 114. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 115. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 116. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 117. MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 118. MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY INDICATION, USD MILLION (2030-2035)
- TABLE 119. SOUTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY INDICATION, USD MILLION (2022-2029)
- TABLE 120. SOUTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET BY BY INDICATION, USD MILLION (2030-2035)
LIST OF FIGURES
- FIGURE 1. MARKET OVERVIEW
- FIGURE 2. REGIONAL SHARE
- FIGURE 3. MARKET REVENUE (USD MILLION)
- FIGURE 4. DROC OF ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET ANALYSIS
- FIGURE 5. SWOT ANALYSIS
- FIGURE 6. PESTEL ANALYSIS
- FIGURE 7. PORTER'S FIVE FORCES ANALYSIS
- FIGURE 8. COVID V, U, W AND L ANALYSIS
- FIGURE 9. LEADING COMPANIES
- FIGURE 10. REGIONAL ANALYSIS
- FIGURE 11. COUNTRY ANALYSIS
- FIGURE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 14. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION), BY REGION
- FIGURE 15. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, (2026), BY REGION
- FIGURE 16. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION), BY REGION
- FIGURE 17. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, (2035), BY REGION
- FIGURE 18. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 19. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 20. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 21. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 22. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 23. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 24. MIDDLE EAST AND AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 25. MIDDLE EAST AND AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 26. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 27. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 28. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 29. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, (2026), BY COUNTRY
- FIGURE 30. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 31. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, (2035), BY COUNTRY
- FIGURE 32. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 33. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 34. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 35. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 36. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 37. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 38. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 39. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, (2026), BY COUNTRY
- FIGURE 40. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 41. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, (2035), BY COUNTRY
- FIGURE 42. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 43. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 44. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 45. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 46. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 47. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 48. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 49. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 50. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 51. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 52. REST OF EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 53. REST OF EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 54. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 55. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, (2026), BY COUNTRY
- FIGURE 56. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 57. ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, (2035), BY COUNTRY
- FIGURE 58. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 59. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 60. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 61. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 62. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 63. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 64. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 65. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 66. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 67. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 68. REST OF ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 69. REST OF ASIA PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 70. MIDDLE EAST AND AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 71. MIDDLE EAST AND AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, (2026), BY COUNTRY
- FIGURE 72. MIDDLE EAST AND AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 73. MIDDLE EAST AND AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, (2035), BY COUNTRY
- FIGURE 74. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 75. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 76. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 77. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 78. REST OF MEA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 79. REST OF MEA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 80. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 81. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, (2026), BY COUNTRY
- FIGURE 82. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 83. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, (2035), BY COUNTRY
- FIGURE 84. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 85. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 86. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 87. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
- FIGURE 88. REST OF LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2022-2029), (USD MILLION)
- FIGURE 89. REST OF LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, (2030-2035), (USD MILLION)
Research Methodology
Our research methodology is carefully designed to deliver the clients with the most accurate, relevant, and actionable market insights to enable clear decision-making and leveraging of opportunities in the markets. We believe consistency, depth in analysis, and a tailored approach in each report are what help set us apart in the industry. The research methodology is based on an integrating research process consisting of in-depth data collection, a complex analysis, and a stringent validation system.
Data Collection
Data collection forms the basis of our study and gathers diverse authentic data to build the basis for deeper study in terms of market trends, competitive landscape, and growth prospects. Data collection takes place through two channels of main activities as follows:
Primary Data Collection
Primary data collection allows collecting real-time and firsthand information from market participants. This is an engagement process conducted by our team with other industry stakeholders, where a much deeper insight than any published data is pursued. This process includes:
- Direct Interviews – We interview the key decision-makers such as CEOs, product managers, innovation heads, and marketing directors to gather both qualitative and quantitative information. The questionnaire covers emerging trends, customer preferences, regulatory impact, and competitors’ strategies.
- Demand and Supply-Side Inputs – Interviews and surveys with supply and demand-side stakeholders provide a balanced view of prevailing market conditions, including feedback from manufacturers, distributors, suppliers, and end-users.
- Expert Opinions – Consultations with industry experts and domain specialists provide insights into future market direction, risks, and opportunities.
- Focus Groups and Online Surveys – Focus groups and surveys are used to understand consumer preferences and adoption probability of new products or services.
Primary research forms the core of our data validation process by offering direct insights into the market, addressing limitations in secondary data, and allowing for an adaptable research process.
Secondary Data Collection
Secondary research serves as a robust foundation for understanding market context, historical data, and larger trends. It involves systematic gathering of existing information from verified sources.
- Industry Reports and Publications – Market reports, white papers, and case studies from credible sources provide a broad view of the market landscape and key players.
- Government and Public Records – Data from government agencies and regulatory bodies helps analyze economic factors and policy impacts.
- News and Media Outlets – Monitoring news articles, press releases, and media reports keeps us updated on market developments and M&A activity.
- Proprietary and Paid Databases – Databases such as Bloomberg, Factiva, D&B Hoovers, and Thomson Reuters provide validated and cross-referenced data.
- Financial Reports and SEC Filings – Financial statements, annual reports, and investor presentations provide insights into revenue structures and profitability.
This combination of primary and secondary data sources enables us to provide a comprehensive view of the market, supported by authenticated information across multiple sources.
Data Analysis Techniques
With the data collected, we initiate a rigorous analysis phase. We analyze market dynamics, growth patterns, and future performance using analytical models and statistical tools.
Top-Down and Bottom-Up Market Sizing Approaches
- Top-Down Approach – Starts with global market size and distributes it across segments using macro-level trends and established proportions.
- Bottom-Up Approach – Aggregates company-level and country-level revenue data to build regional and global market estimates.
These two approaches are cross-validated to remove inconsistencies and ensure accurate market estimation.
Forecasting Models and Market Dynamics Analysis
- Time-Series Analysis – Models historical trends, seasonality, and demand cycles.
- Econometric and Judgmental Forecasting – Combines economic models with expert-driven adjustments.
- Delphi Method – Uses iterative expert input to generate balanced market forecasts.
Data Triangulation and Validation
- Multi-source cross-verification of all data points
- Use of quantitative and qualitative validation techniques
- Sample validation through expert and stakeholder feedback
Market Analysis and Sizing Estimation
- Detailed segmentation analysis
- Competitive landscape evaluation
- Revenue modeling using TAM, SAM, and SOM frameworks
Quality Assurance and Final Review
- Data accuracy and consistency checks
- Content, language, and structure review
- Client-specific customization and refinement
Continuous Improvement in Methodology
We continuously refine our research methodologies based on evolving market conditions, client feedback, and technological advancements. This ensures our research remains accurate, relevant, and aligned with industry standards.
Advanced Therapy Medicinal Products CDMO Market Report Scope & Segmentation
| Attributes | Details |
|---|---|
| Market Size (Current)Current market valuation | US$ 11.12 Billion in 2026 |
| Market Size (Forecast)Projected market valuation | US$ 53.11 Billion in 2035 |
| Growth RateCompound Annual Growth Rate | CAGR of 18.97% from 2026 to 2035 |
| Forecast PeriodAnalysis timeline | 2026 – 2035 |
| Base YearReference year for analysis | 2025 |
| Historical Data AvailablePast market data availability | Yes |
| Regional ScopeGeographical coverage | Global |
| Segments CoveredMarket segments analyzed | By Product
By Phase
By Indication
|
Leading companies covered in this report
- Lonza
- Catalent
- WuXi Advanced Therapies
- Thermo Fisher (Brammer Bio)
- Charles River
- Fujifilm Diosynth
- Hitachi Chemical
Frequently Asked Questions
Common questions about this report
The study period covers historical insights and forecast projections for the period 2026-2035.
The global Advanced Therapy Medicinal Products CDMO Market market is expected to grow at a CAGR of 18.97% during the forecast period 2026-2035.
The report offers comprehensive market segmentation analysis across key categories and sub-segments relevant to the industry, along with regional and competitive insights.
The market is projected to reach 53.11 Billion by 2035.
Key players in the Advanced Therapy Medicinal Products CDMO Market include Lonza, Catalent, WuXi Advanced Therapies, Thermo Fisher (Brammer Bio), Charles River, Fujifilm Diosynth, and Hitachi Chemical.
North America, Europe, and Asia Pacific are key regions covered in the report, including regional trends, market share, and growth opportunities.
Growing demand, technological advancements, changing consumer preferences, and increasing investments are some of the major factors supporting the growth of the Advanced Therapy Medicinal Products CDMO Market market.
Yes, the report includes company profiling, competitive landscape analysis, strategic developments, mergers & acquisitions, product launches, and market positioning of leading industry participants.
The report is prepared using a combination of primary research, secondary research, expert interviews, industry databases, company annual reports, and proprietary market analysis models.
Yes, report customization options are available based on specific business objectives, geographic focus, competitive benchmarking requirements, and additional market segmentation needs.
Yes, the report is available in both PDF and Excel formats. The Excel file includes all market data tables, forecasts, and segment-wise data for easy analysis.
Yes, you can request a free sample report which includes an overview, table of contents, and sample data pages to help you evaluate the report before making a purchase decision.
About the Author
Market research expert with years of industry experience
Dipali Bhingare serves as the Market Research Director at Econ Market Research. With a focus on translating complex global economic shifts into actionable business intelligence, she oversees the strategic direction of comprehensive market studies. Her work empowers organizations to navigate volatile industries through data-driven forecasting and deep-dive competitive analysis.
